The New Experimental Cancer Vaccine has proven 100% effective on mouse.
Cancer is a term for disease caused by an uncontrolled division of abnormal cells in the parts of our body. Many scientist worked hard to understand how cancer forms, how to develop strategies to prevent it, treatments and how to cure it. Cancer is one of the leading cause of death in the world (According to Our World in Data the number of people died in cancer are almost 8.93 million annually.) For years now, researchers have studied thoroughly on how to stop this deadly disease. At present, the different types of cancer treatment are Surgery, Chemotherapy, Radiation Therapy & Immunotherapy
According to WHO, over the past decades the incidence of melanoma and non-melanoma skin cancers has fleetingly increased. An estimated 132,000 are diagnosed with Melanoma & 2-3 million non-melanoma skin cancer, resulting in more than 3,000 deaths per year.
Researchers are striving hard to find treatment to this deadly disease. This September 2018 researchers from the Scripps Research Institute in San Diego, CA, recently worked with experts from other institutions to develop a vaccine that would be effective against melanoma, A new cancer vaccine appears to fight off a deadly skin cancer. This could be a game changer!
The experimental approach was a huge success. The mice with an aggressive melanoma was given three different therapy options and all of the mice was given a type of cancer immunotherapy called anti-PD-L1, which is meant to prevent tumour cells from evading the host’s immune system, but in addition to this each mice will receive different vaccine variants.
The first therapy was given to a group of mice, who got only anti-PD-L1 and an injection of ovalbumin, the latter of which was meant to train their immune systems to recognise the tumour as an intruder.
The second group, was the same with the first group but also received chemical Diprovocim added to the ovalbumin injection, as a means to stimulate the immune system into action.
Lastly, the group of mice was received both the anti-PD-L1 and the ovalbumin, but with the compound alum added instead of Diprovocim; alum also activates the immune system, but in a different way to Diprovocim. Amazingly, the mice that received the cancer vaccine plus Diprovocim had a 100% survival rate over 54 days, whereas the mice who received the cancer vaccine with no Diprovocim had a 0% survival rate.
The researchers plan to do further preclinical testing with this vaccine design and study how it works in combination with other cancer therapies.